Name of Protocol

Phase Ib/IIa Trial to Evaluate Oregovomab and Nivolumab in Epithelial Cancer of Ovarian, Tubal or Peritoneal Origin (ORION-01)


The purpose of this 32-patient open label single arm study is to characterize the safety and tolerability of oregovomab in combination with nivolumab as a novel combinatorial immunotherapeutic strategy in female patients with recurrent epithelial ovarian cancer (EOC) who have progressed after two or more prior lines of cytotoxic chemotherapy.


This study began enrolling patients in February 2017 and is expected to be completed in December 2019.

Participating Centers

National Cancer Centre of Singapore
Singapore, Singapore